NEW YORK, July 31, 2017 /PRNewswire/ --
If you want a Stock Review on AKTX, FLXN, LCI, or SUPN then come over tohttp://dailystocktracker.com/register/ and sign up for your free customized report today. On Friday, July 28, 2017, the NASDAQ Composite and the S&P 500 edged 0.12% and 0.13% lower, respectively at the closing bell,
Shares in New York-based Akari Therapeutics PLC ended Friday's session 2.89% higher at $4.63 with a total trading volume of 86,177 shares. The Company's shares are trading below their 50-day moving average by 13.22%. Moreover, shares of Akari Therapeutics, which focuses on the development and commercialization of therapeutics to treat rare and orphan autoimmune and inflammatory diseases, have a Relative Strength Index (RSI) of 44.60. See our free and comprehensive research report on AKTX at:
Burlington, Massachusetts headquartered Flexion Therapeutics Inc.'s shares saw a rise of 1.13%, closing the day at $24.10. A total volume of 264,561 shares was traded. The stock has advanced 11.78% in the last month, 18.08% in the previous three months, 45.01% over the past twelve months, and 26.71% on an YTD basis. The Company's shares are trading above their 50-day and 200-day moving averages by 19.78% and 18.20%, respectively. Additionally, shares of Flexion Therapeutics, which focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions, have an RSI of 63.91. FLXN free research report PDF is just a click away at:
Last Friday, shares in Philadelphia, Pennsylvania-based Lannett Co. Inc. gained 0.49%, closing the session at $20.70. The stock recorded a trading volume of 258,554 shares. The stock is trading above its 50-day moving average by 2.04%. Furthermore, shares of Lannett, which develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products in the US, have an RSI of 47.44%. Sign up for your complimentary report on LCI at:
Rockville, Maryland-based Supernus Pharmaceuticals Inc.'s stock finished the session 0.24% lower at $41.00 with a total trading volume of 579,942 shares. The Company's shares have advanced 25.77% over the previous three months, 81.98% in the past twelve months, and 62.38% on YTD basis. The stock is trading above its 50-day and 200-day moving averages by 1.46% and 37.98%, respectively. Additionally, shares of Supernus Pharma, which focuses on the development and commercialization of products for the treatment of central nervous system diseases in the US, have an RSI of 44.24.
On July 17th, 2017, research firm Piper Jaffray downgraded the Company's stock rating from 'Overweight' to 'Neutral'. Register for free on DailyStockTracker.com and download the latest research report on SUPN at:
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: email@example.com Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Cachexia refers to severe muscle and fat loss, anorexia and marked weight loss due to an underlying ...
Exotropia or outward eye deviation is a form of squint. Proper evaluation and timely intervention ...
Glaucoma is a group of disorders involving the optic nerve, often associated with a rise in ...View All